Across TCGA pan-cancer cohorts, MTND5P18 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTND5P18 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MTND5P18 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND5P18 expression acts as an unfavorable survival marker, although some lineages such as ESCA and TGCT show a favorable association.
LIHC, KIRC, and ACC are the cancer types where MTND5P18 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.